Top

Published in:

Open Access 01-12-2010 | Review

RTehvieew impact of antiretroviral therapy on HPV andcervical intraepithelial neoplasia: current evidence and directions for future research

Authors: Lara F Bratcher, Vikrant V Sahasrabuddhe

Published in: Infectious Agents and Cancer | Issue 1/2010

Abstract

Increasing numbers of human immunodeficiency virus (HIV)-infected women are now accessing life-prolonging highly active antiretroviral therapy (HAART) in developing countries. There is a need for better understanding of interactions of human papillomavirus (HPV) and HIV, especially in the context of increasing life expectancy due to HAART. The data regarding the impact of HAART on reducing the incidence and progression and facilitating the regression of HPV infection and cervical abnormalities is largely inconsistent. Published studies differ in their study designs (prospective or retrospective cohorts or record linkage studies), screening and diagnostic protocols, duration and type of HAART use, recruitment and referral strategies, and definitions of screening test and disease positivity. Due to the ethical and resource limitations in conducting randomized trials of the impact of HAART on incidence of HPV, CIN, and cervical cancer among HIV-infected women, it is important to consider innovative study designs, including quasi-experimental trials and operations research in sentinel populations to answer the critical research questions in this area.

Available only for authorised users

Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.PubMedCrossRef

Hawes SE, Critchlow CW, Faye Niang MA, Diouf MB, Diop A, Toure P, Aziz Kasse A, Dembele B, Salif Sow P, Coll-Seck AM, et al: Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis. 2003, 188: 555-563. 10.1086/376996.PubMedCrossRef

Massad LS, Seaberg EC, Watts DH, Minkoff H, Levine AM, Henry D, Colie C, Darragh TM, Hessol NA: Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer. 2009, 115: 524-530. 10.1002/cncr.24067.PubMedPubMedCentralCrossRef

Adam Y, van Gelderen CJ, de Bruyn G, McIntyre JA, Turton DA, Martinson NA: Predictors of persistent cytologic abnormalities after treatment of cervical intraepithelial neoplasia in Soweto, South Africa: a cohort study in a HIV high prevalence population. BMC Cancer. 2008, 8: 211-10.1186/1471-2407-8-211.PubMedPubMedCentralCrossRef

Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR: Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009, 51: 274-282. 10.1097/QAI.0b013e3181a97be5.PubMedPubMedCentralCrossRef

Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, Hall C, Bacon M, Levine AM, Watts DH, et al: Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005, 97: 577-586. 10.1093/jnci/dji073.PubMedCrossRef

Gingelmaier A, Grubert T, Kaestner R, Mylonas I, Weissenbacher T, Bergauer F, Barthell L, Friese K: High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. Anticancer Res. 2007, 27: 1795-1798.PubMed

Palefsky JM, Holly EA: Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr. 2003, 41-46.

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000, 92: 1823-1830. 10.1093/jnci/92.22.1823.

10.

Dorrucci M, Suligoi B, Serraino D, Tirelli U, Rezza G: Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001, 26: 377-380.PubMedCrossRef

11.

Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006, 20: 1645-1654. 10.1097/01.aids.0000238411.75324.59.PubMedCrossRef

12.

Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008, 123: 187-194. 10.1002/ijc.23487.PubMedCrossRef

13.

Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, Moxley M, Palefsky J, Sacks H, Burk RD, Gange SJ: Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2004, 96: 1070-1076. 10.1093/jnci/djh192.PubMedCrossRef

14.

Del Mistro A, Bertorelle R, Franzetti M, Cattelan A, Torrisi A, Giordani MT, Sposetti R, Bonoldi E, Sasset L, Bonaldi L, et al: Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis. 2004, 38: 737-742. 10.1086/381681.PubMedCrossRef

15.

Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, Mastrorilli E, Taccagni G, Lazzarin A, Uberti-Foppa C: Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis. 2001, 184: 547-551. 10.1086/322856.PubMedCrossRef

16.

Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007, 99: 962-972. 10.1093/jnci/djm010.PubMedCrossRef

17.

Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, Muderspach L, Burk R, Palefsky J: The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS. 2001, 15: 2157-2164. 10.1097/00002030-200111090-00011.PubMedCrossRef

18.

Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000, 132: 810-819.PubMedCrossRef

19.

Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, et al: Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer. 2009, 100: 840-847. 10.1038/sj.bjc.6604923.PubMedPubMedCentralCrossRef

20.

Soncini E, Zoncada A, Condemi V, Antoni AD, Bocchialini E, Soregotti P: Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed. 2007, 78: 36-40.PubMed

21.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, et al: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005, 97: 425-432. 10.1093/jnci/dji072.PubMedCrossRef

22.

Heard I, Potard V, Costagliola D: Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women. Antivir Ther. 2006, 11: 1091-1096.PubMed

23.

Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, Rompalo AM, Cu-Uvin S, Duerr A: The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol. 2009, 113: 26-31.PubMedCrossRef

24.

Sirera G, Videla S, Lopez-Blazquez R, Llatjos M, Tarrats A, Castella E, Grane N, Alcalde C, Tural C, Rey-Joly C, Clotet B: Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era. AIDS Res Hum Retroviruses. 2007, 23: 965-971. 10.1089/aid.2006.0293.PubMedCrossRef

25.

Schuman P, Ohmit SE, Klein RS, Duerr A, Cu-Uvin S, Jamieson DJ, Anderson J, Shah KV: Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003, 188: 128-136. 10.1086/375783.PubMedCrossRef

26.

Moore AL, Sabin CA, Madge S, Mocroft A, Reid W, Johnson MA: Highly active antiretroviral therapy and cervical intraepithelial neoplasia. AIDS. 2002, 16: 927-929. 10.1097/00002030-200204120-00014.PubMedCrossRef

27.

Heard I, Tassie JM, Kazatchkine MD, Orth G: Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS. 2002, 16: 1799-1802. 10.1097/00002030-200209060-00013.PubMedCrossRef

28.

Sirera G, Videla S, Lopez-Blazquez R, Llatjos M, Tarrats A, Castella E, Grane N, Tural C, Rey-Joly C, Clotet B: Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3. J Antimicrob Chemother. 2008, 61: 191-194. 10.1093/jac/dkm412.PubMedCrossRef

29.

Ferguson M, Wilkinson DE, Zhou T: WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine. 2009, 27: 337-347. 10.1016/j.vaccine.2008.10.062.PubMedCrossRef

30.

Palefsky J: Human papillomavirus infection in HIV-infected persons. Top HIV Med. 2007, 15: 130-133.PubMed

31.

Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, Wright TC: Incidence of cervical squamous intraepithelial lesions in HIV-infected women. Jama. 2000, 283: 1031-1037. 10.1001/jama.283.8.1031.PubMedCrossRef

32.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.PubMedCrossRef

33.

Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD: Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS. 1998, 12: 1459-1464. 10.1097/00002030-199812000-00007.PubMedCrossRef

34.

Heard I, Potard V, Foulot H, Chapron C, Costagliola D, Kazatchkine MD: High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr. 2005, 39: 412-418. 10.1097/01.qai.0000167157.83098.60.PubMedCrossRef

35.

Robinson WR, Hamilton CA, Michaels SH, Kissinger P: Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol. 2001, 184: 538-543. 10.1067/mob.2001.111103.PubMedCrossRef

36.

Meys R, Gotch FM, Bunker CB: Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease?. Br J Dermatol. 2009

37.

Vernon SD, Hart CE, Reeves WC, Icenogle JP: The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res. 1993, 27: 133-145. 10.1016/0168-1702(93)90077-Z.PubMedCrossRef

38.

Tornesello ML, Buonaguro FM, Beth-Giraldo E, Giraldo G: Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression. Intervirology. 1993, 36: 57-64.PubMed

39.

Spinillo A, Tenti P, Zappatore R, De Seta F, Silini E, Guaschino S: Langerhans' cell counts and cervical intraepithelial neoplasia in women with human immunodeficiency virus infection. Gynecol Oncol. 1993, 48: 210-213. 10.1006/gyno.1993.1035.PubMedCrossRef

40.

Olaitan A, Johnson MA, MacLean A, Poulter LW: The distribution of immunocompetent cells in the genital tract of HIV-positive women. AIDS. 1996, 10: 759-764. 10.1097/00002030-199606001-00010.PubMedCrossRef

41.

Nicol AF, Nuovo GJ, Salomao-Estevez A, Grinsztejn B, Tristao A, Russomano F, Lapa ESJR, Oliveira MP, Pirmez C: Immune factors involved in the cervical immune response in the HIV/HPV co-infection. J Clin Pathol. 2008, 61: 84-88. 10.1136/jcp.2007.047290.PubMedCrossRef

42.

Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B: Antitumour effects of antiretroviral therapy. Nat Rev Cancer. 2004, 4: 861-875. 10.1038/nrc1479.PubMedCrossRef

43.

Deapen D, Cockburn M, Pinder R, Lu S, Wohl AR: Population-based linkage of AIDS and cancer registries: importance of linkage algorithm. Am J Prev Med. 2007, 33: 134-136. 10.1016/j.amepre.2007.03.015.PubMedCrossRef

44.

Lopez AD, Mathers CD: Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol. 2006, 100: 481-499. 10.1179/136485906X97417.PubMedCrossRef

45.

Abdool Karim SS, Abdool Karim Q, Gouws E, Baxter C: Global epidemiology of HIV-AIDS. Infect Dis Clin North Am. 2007, 21: 1-17. 10.1016/j.idc.2007.01.010. vii.PubMedCrossRef

46.

Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, Mudenda V, Hicks ML, Vermund SH, Stringer JS, Parham GP: Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia. AIDS. 2009, 23: N1-5. 10.1097/QAD.0b013e3283236e11.PubMedPubMedCentralCrossRef

47.

Pfaendler KS, Mwanahamuntu MH, Sahasrabuddhe VV, Mudenda V, Stringer JS, Parham GP: Management of cryotherapy-ineligible women in a "screen-and-treat" cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field. Gynecol Oncol. 2008, 110: 402-407. 10.1016/j.ygyno.2008.04.031.PubMedPubMedCentralCrossRef

48.

Mwanahamuntu MH, Sahasrabuddhe VV, Parham GP: HPV screening for cervical cancer in rural India. N Engl J Med. 2009, 361: 305-author reply 306.PubMedPubMedCentral

49.

Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, Chipato T, Ngwalle S, Munjoma M, Shah KV: HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer. 2000, 85: 206-210.PubMedCrossRef

50.

Franceschi S, Jaffe H: Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis. 2007, 45: 510-513. 10.1086/520022.PubMedCrossRef

51.

Questions and Answers: The CIPRA HT001 Clinical Trial. [http://www3.niaid.nih.gov/news/QA/CIPRA_HT01_qa.htm]

52.

HPTN 052: A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples. [http://www.hptn.org/research_studies/hptn052.asp]

Title: RTehvieew impact of antiretroviral therapy on HPV andcervical intraepithelial neoplasia: current evidence and directions for future research
Authors: Lara F Bratcher
Vikrant V Sahasrabuddhe
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Infectious Agents and Cancer / Issue 1/2010
Electronic ISSN: 1750-9378
DOI: https://doi.org/10.1186/1750-9378-5-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda

Incidence and mortality rates of selected infection-related cancers in Puerto Rico and in the United States

Association of LEC and tnpA Helicobacter pylori genes with gastric cancer in a Brazilian population

Rapid, sensitive, type specific PCR detection of the E7 region of human papillomavirus type 16 and 18 from paraffin embedded sections of cervical carcinoma

Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer

Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer